Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of non-myeloid malignancy~* Baseline hemoglobin value of \<= 11 g/dL unrelated to transfusion~* Planned chemotherapy for a minimum of 12 weeks during the study~* Life expectancy of \>= 6 months~* ECOG Performance Status 0-2~Exclusion Criteria:~* Diagnosis of a myeloid malignancy or known history of myelodysplasia~* Planned non-palliative radiation during the study~* Anemia due to factors other than cancer/chemotherapy~* Prior treatment with Epoetin alfa or any other erythropoietic agent within the previous three months~* History of uncontrolled cardiac arrhythmias or history of pulmonary emboli, deep vein thrombosis, ischemic stroke, other arterial or venous thrombotic events (excluding superficial thromboses), or known history of chronic coagulation disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).